Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis
Open Access
- 15 November 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 45 (1), 106-111
- https://doi.org/10.1093/rheumatology/kei193
Abstract
Objective. To compare antibody responses to 23-valent pneumococcal vaccine (Pneumovax®) in controls and patients with established rheumatoid arthritis (RA) treated with TNF blockers, methotrexate (MTX) or a combination of both. Methods. Patients with RA (n = 149) and healthy controls (n = 47) were vaccinated. Treatment with TNF blockers (etanercept or infliximab) and MTX was given to 50 patients, and 62 patients were treated with TNF blockers alone or with other DMARDs. MTX alone was given to 37 patients. Concentrations of immunoglobulin G (IgG) antibodies against pneumococcal capsular polysaccharides 23F and 6B were measured by enzyme-linked immunoassay before and 4–6 weeks after vaccination. An immune response was defined as a twofold or higher increase in antibody concentration following vaccination. Results. Prevaccination antibody levels for both 23F and 6B were similar in the patient groups. Antibody concentrations after vaccination increased significantly in all groups. Patients treated with TNF blockers without MTX showed better immune responses than those treated with TNF blockers in combination with MTX (P = 0.037 for 23F and P = 0.004 for 6B) or MTX alone (PConclusions. Patients treated with TNF blockers and controls showed similar responses to vaccination. In contrast, patients treated with MTX had reduced responses regardless of anti-TNF treatment. The findings do not argue against the use of pneumococcal vaccination in RA patients undergoing treatment with TNF blockers.Keywords
This publication has 40 references indexed in Scilit:
- Vaccines for preventing pneumococcal infection in adultsPublished by Wiley ,2003
- Multistate Evaluation of Invasive Pneumococcal Diseases in Adults with Human Immunodeficiency Virus Infection: Serotype and Antimicrobial Resistance Patterns in the United StatesThe Journal of Infectious Diseases, 2003
- Infectious complications of biologic treatments of rheumatoid arthritisCurrent Opinion in Rheumatology, 2003
- Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern SwedenAnnals Of The Rheumatic Diseases, 2002
- Immunogenicity and Safety of Pneumococcal Vaccination in Patients with Rheumatoid Arthritis or Systemic Lupus ErythematosusClinical Infectious Diseases, 2002
- Report of the EULAR Standing Committee for International clinical Studies Including therapeutic Trials (ESCISIT)Annals Of The Rheumatic Diseases, 2001
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Development and validation of the european league against rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary american college of rheumatology and the world health organization/international league against rheumatism criteriaArthritis & Rheumatism, 1996
- The mortality of rheumatoid arthritisArthritis & Rheumatism, 1994
- Efficacy of Pneumococcal Vaccine in High-Risk PatientsNew England Journal of Medicine, 1986